## WIKINGO Proyect Systematic Analysis

## Tables & Figures.

Proyecto Vikingo September 30, 2016

proyectovikingo@proyectovikingo.es

WIKINGO Project	September 30, 2016	Systematic analysis	2

(	٦,	'n	te	n	+0
ı	7	) I I	ьe	: 1 1	1.5

$\mathbf{List}$	of Tables	
1	Participant characteristics	

## List of Figures

3

Table 1: Participant characteristics

Age   68.6 (12.1)   48	 		
N=48           Age         68.6 (12.1)         48           Sex: Men         33 (68.8%)         48           Tumor level:         48           0-6cm         18 (37.5%)           7-11cm         23 (47.9%)           12-15cm         7 (14.6%)           Tumor stage:         48           0         5 (10.4%)           I         15 (31.2%)           III         13 (27.1%)           III         15 (31.2%)           Neoadjuvant treatment         26 (54.2%)         48           Type of resection:         48           Abdominoperineal resection         10 (20.8%)           Anterior resection         36 (75.0%)           Hartmann         2 (4.17%)           Perforation         2 (4.17%)         48           Invasion circumferential margin         6 (12.5%)         48           Mesorrecto quality:         47           Satisfactory         29 (61.7%)         48           No-satisfactory         2 (4.26%)         48           Months to recidive         1 (2.08%)         48           Months to Metastasis         7 (14.6%)         48           Months to Metastasis         14.0 [3.75;20.0]		_	N
Sex: Men       33 (68.8%)       48         Tumor level:       48         0-6cm       18 (37.5%)         7-11cm       23 (47.9%)         12-15cm       7 (14.6%)         Tumor stage:       48         0       5 (10.4%)         II       15 (31.2%)         III       13 (27.1%)         III       15 (31.2%)         Neoadjuvant treatment       26 (54.2%)       48         Type of resection:       48         Abdominoperineal resection       10 (20.8%)       48         Anterior resection       36 (75.0%)       48         Hartmann       2 (4.17%)       48         Invasion circumferential margin       6 (12.5%)       48         Mesorrecto quality:       29 (61.7%)         Partial       16 (34.0%)       47         Satisfactory       29 (61.7%)       48         No-satisfactory       2 (4.26%)       48         Recidive       1 (2.08%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%) <td< td=""><td> </td><td>N=48</td><td></td></td<>	 	N=48	
Tumor level: 48 0-6cm 18 (37.5%) 7-11cm 23 (47.9%) 12-15cm 7 (14.6%)  Tumor stage: 48 0 5 (10.4%) I 15 (31.2%) III 13 (27.1%) III 15 (31.2%) Neoadjuvant treatment 26 (54.2%) 48 Type of resection: 48 Abdominoperineal resection Anterior resection 36 (75.0%) Hartmann 2 (4.17%) Perforation 2 (4.17%) 48 Invasion circumferential margin 6 (12.5%) 48 Mesorrecto quality: 47 Satisfactory 29 (61.7%) Partial 16 (34.0%) No-satisfactory 2 (4.26%) Recidive 1 (2.08%) 48 Months to recidive 15.0 [4.75;22.0] 48 Metastasis 7 (14.6%) 48 Months to Metastasis 14.0 [3.75;20.0] 48 Exitus 2 (4.17%) 48	Age	68.6 (12.1)	48
0-6cm       18 (37.5%)         7-11cm       23 (47.9%)         12-15cm       7 (14.6%)         Tumor stage:       48         0       5 (10.4%)         I       15 (31.2%)         III       13 (27.1%)         III       15 (31.2%)         Neoadjuvant treatment       26 (54.2%)       48         Type of resection:       48         Abdominoperineal resection       10 (20.8%)         Anterior resection       36 (75.0%)         Hartmann       2 (4.17%)       48         Invasion circumferential margin       6 (12.5%)       48         Mesorrecto quality:       47       47         Satisfactory       29 (61.7%)       48         No-satisfactory       2 (4.26%)       48         No-satisfactory       2 (4.26%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	Sex: Men	33~(68.8%)	48
7-11cm 23 (47.9%) 12-15cm 7 (14.6%)  Tumor stage: 48 0 5 (10.4%) I 15 (31.2%) III 13 (27.1%) III 15 (31.2%) Neoadjuvant treatment 26 (54.2%) 48 Type of resection: 48 Abdominoperineal resection 10 (20.8%) Anterior resection 36 (75.0%) Hartmann 2 (4.17%) Perforation 2 (4.17%) Perforation 2 (4.17%) 48 Invasion circumferential margin 6 (12.5%) 48 Mesorrecto quality: 47 Satisfactory 29 (61.7%) Partial 16 (34.0%) No-satisfactory 2 (4.26%) Recidive 1 (2.08%) 48 Months to recidive 15.0 [4.75;22.0] 48 Metastasis 7 (14.6%) 48 Months to Metastasis 14.0 [3.75;20.0] 48 Exitus 2 (4.17%) 48	Tumor level:		48
Tumor stage: 48  0 5 (10.4%)  I 15 (31.2%)  II 13 (27.1%)  III 15 (31.2%)  Neoadjuvant treatment 26 (54.2%) 48  Type of resection: 48  Abdominoperineal resection 10 (20.8%)  Anterior resection 36 (75.0%)  Hartmann 2 (4.17%)  Perforation 2 (4.17%)  Perforation 2 (4.17%) 48  Invasion circumferential margin 6 (12.5%) 48  Mesorrecto quality: 47  Satisfactory 29 (61.7%)  Partial 16 (34.0%)  No-satisfactory 2 (4.26%)  Recidive 1 (2.08%) 48  Months to recidive 15.0 [4.75;22.0] 48  Metastasis 7 (14.6%) 48  Months to Metastasis 14.0 [3.75;20.0] 48  Exitus 2 (4.17%) 48	0-6cm	18 (37.5%)	
Tumor stage:  0	7-11cm	23~(47.9%)	
0       5 (10.4%)         I       15 (31.2%)         III       13 (27.1%)         III       15 (31.2%)         Neoadjuvant treatment       26 (54.2%)         Type of resection:       48         Abdominoperineal resection       10 (20.8%)         Anterior resection       36 (75.0%)         Hartmann       2 (4.17%)         Perforation       2 (4.17%)         Perforation invasion circumferential margin       6 (12.5%)         Mesorrecto quality:       47         Satisfactory       29 (61.7%)         Partial       16 (34.0%)         No-satisfactory       2 (4.26%)         Recidive       1 (2.08%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	$12\text{-}15\mathrm{cm}$	7 (14.6%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Tumor stage:		48
III       13 (27.1%)         III       15 (31.2%)         Neoadjuvant treatment       26 (54.2%)       48         Type of resection:       48         Abdominoperineal resection       10 (20.8%)         Anterior resection       36 (75.0%)         Hartmann       2 (4.17%)         Perforation       2 (4.17%)         Perforation invasion circumferential margin       6 (12.5%)         Mesorrecto quality:       47         Satisfactory       29 (61.7%)         Partial       16 (34.0%)         No-satisfactory       2 (4.26%)         Recidive       1 (2.08%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	0	5 (10.4%)	
III       15 (31.2%)         Neoadjuvant treatment       26 (54.2%)       48         Type of resection:       48         Abdominoperineal resection       10 (20.8%)         Anterior resection       36 (75.0%)         Hartmann       2 (4.17%)         Perforation       2 (4.17%)       48         Invasion circumferential margin       6 (12.5%)       48         Mesorrecto quality:       47       47         Satisfactory       29 (61.7%)       48         Partial       16 (34.0%)       48         No-satisfactory       2 (4.26%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	I	15(31.2%)	
Neoadjuvant treatment       26 (54.2%)       48         Type of resection:       48         Abdominoperineal resection       10 (20.8%)         Anterior resection       36 (75.0%)         Hartmann       2 (4.17%)         Perforation       2 (4.17%)       48         Invasion circumferential margin       6 (12.5%)       48         Mesorrecto quality:       29 (61.7%)       47         Satisfactory       29 (61.7%)       48         No-satisfactory       2 (4.26%)       48         Recidive       1 (2.08%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	II	13 (27.1%)	
Type of resection:       48         Abdominoperineal resection       10 (20.8%)         Anterior resection       36 (75.0%)         Hartmann       2 (4.17%)         Perforation       2 (4.17%)       48         Invasion circumferential margin       6 (12.5%)       48         Mesorrecto quality:       47         Satisfactory       29 (61.7%)         Partial       16 (34.0%)         No-satisfactory       2 (4.26%)         Recidive       1 (2.08%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	III	15 (31.2%)	
Abdominoperineal resection Anterior resection Anterior resection Hartmann 2 (4.17%) Perforation 2 (4.17%) 48 Invasion circumferential margin Mesorrecto quality: Satisfactory Partial No-satisfactory Partial 16 (34.0%) No-satisfactory 2 (4.26%) Recidive 1 (2.08%) 48 Months to recidive 15.0 [4.75;22.0] 48 Metastasis 7 (14.6%) 48 Months to Metastasis 14.0 [3.75;20.0] 48 Exitus 2 (4.17%) 48	Neoadjuvant treatment	26 (54.2%)	48
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Type of resection:		48
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Abdominoperineal rese	ection $10 (20.8\%)$	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Anterior resection	36~(75.0%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Hartmann	2(4.17%)	
Mesorrecto quality:       47         Satisfactory       29 (61.7%)         Partial       16 (34.0%)         No-satisfactory       2 (4.26%)         Recidive       1 (2.08%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	Perforation	2(4.17%)	48
Satisfactory       29 (61.7%)         Partial       16 (34.0%)         No-satisfactory       2 (4.26%)         Recidive       1 (2.08%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	Invasion circumferential ma	argin 6 (12.5%)	48
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Mesorrecto quality:		47
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Satisfactory	29~(61.7%)	
Recidive       1 (2.08%)       48         Months to recidive       15.0 [4.75;22.0]       48         Metastasis       7 (14.6%)       48         Months to Metastasis       14.0 [3.75;20.0]       48         Exitus       2 (4.17%)       48	Partial	16 (34.0%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	No-satisfactory	2(4.26%)	
Metastasis $7 (14.6\%)$ 48         Months to Metastasis $14.0 [3.75;20.0]$ 48         Exitus $2 (4.17\%)$ 48	Recidive	1(2.08%)	48
Months to Metastasis $14.0 \ [3.75;20.0] \ 48$ Exitus $2 \ (4.17\%) \ 48$	Months to recidive	15.0 [4.75;22.0]	48
Exitus 2 (4.17%) 48	Metastasis	7 (14.6%)	48
,	Months to Metastasis	14.0 [3.75;20.0]	48
Months to exitus 15.0 [5.00;22.0] 48	Exitus	2~(4.17%)	48
	Months to exitus	15.0 [5.00;22.0]	48